Safety and efficacy of generic drugs with respect to brand formulation
Generic drugs are equivalent to the brand formulation if they have the same active substance, the same pharmaceutical form and the same therapeutic indications and a similar bioequivalence respect to the reference medicinal product. The use of generic drugs is indicated from many countries in order to reduce medication price. However some points, such as bioequivalence and the role of excipients, may be clarified regarding the clinical efficacy and safety during the switch from brand to generic formulations. In conclusion, the use of generic drugs could be related with an increased days of disease (time to relapse) or might lead to a therapeutic failure; on the other hand, a higher drug concentration might expose patients to an increased risk of dose-dependent side-effects.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2013 |
|---|---|
| Erschienen: |
2013 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:4 |
|---|---|
| Enthalten in: |
Journal of pharmacology & pharmacotherapeutics - 4(2013), Suppl 1 vom: 01. Dez., Seite S110-4 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Gallelli, Luca [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Antibiotics |
|---|
| Anmerkungen: |
Date Completed 18.12.2013 Date Revised 13.04.2024 published: Print Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.4103/0976-500X.120972 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM233754148 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM233754148 | ||
| 003 | DE-627 | ||
| 005 | 20240413232112.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231224s2013 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.4103/0976-500X.120972 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1374.xml |
| 035 | |a (DE-627)NLM233754148 | ||
| 035 | |a (NLM)24347975 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Gallelli, Luca |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Safety and efficacy of generic drugs with respect to brand formulation |
| 264 | 1 | |c 2013 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 18.12.2013 | ||
| 500 | |a Date Revised 13.04.2024 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a Generic drugs are equivalent to the brand formulation if they have the same active substance, the same pharmaceutical form and the same therapeutic indications and a similar bioequivalence respect to the reference medicinal product. The use of generic drugs is indicated from many countries in order to reduce medication price. However some points, such as bioequivalence and the role of excipients, may be clarified regarding the clinical efficacy and safety during the switch from brand to generic formulations. In conclusion, the use of generic drugs could be related with an increased days of disease (time to relapse) or might lead to a therapeutic failure; on the other hand, a higher drug concentration might expose patients to an increased risk of dose-dependent side-effects | ||
| 650 | 4 | |a Case Reports | |
| 650 | 4 | |a Antibiotics | |
| 650 | 4 | |a bioequivalence | |
| 650 | 4 | |a brand | |
| 650 | 4 | |a clinical efficacy | |
| 650 | 4 | |a generic | |
| 650 | 4 | |a safety | |
| 700 | 1 | |a Palleria, Caterina |e verfasserin |4 aut | |
| 700 | 1 | |a De Vuono, Antonio |e verfasserin |4 aut | |
| 700 | 1 | |a Mumoli, Laura |e verfasserin |4 aut | |
| 700 | 1 | |a Vasapollo, Piero |e verfasserin |4 aut | |
| 700 | 1 | |a Piro, Brunella |e verfasserin |4 aut | |
| 700 | 1 | |a Russo, Emilio |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of pharmacology & pharmacotherapeutics |d 2010 |g 4(2013), Suppl 1 vom: 01. Dez., Seite S110-4 |w (DE-627)NLM206139993 |x 0976-500X |7 nnns |
| 773 | 1 | 8 | |g volume:4 |g year:2013 |g number:Suppl 1 |g day:01 |g month:12 |g pages:S110-4 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.4103/0976-500X.120972 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 4 |j 2013 |e Suppl 1 |b 01 |c 12 |h S110-4 | ||